MRNA cap analogs and uses thereof
By simplifying the synthesis and purification process of cap analogs and using compounds of chemical formula 1 as cap analogs, the efficiency of mRNA synthesis and protein expression is improved, solving the problems of cumbersome synthesis steps and high costs in existing technologies, and realizing economical and efficient mRNA production.
Patent Information
- Application Number
- CN202380032262.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-24
- Filing Date
- 2023-03-10
- Publication Date
- 2024-11-15
AI Technical Summary
In existing technologies, the synthesis of cap analogs is cumbersome and costly, which affects the efficiency and economics of large-scale production of mRNA vaccines, especially when dealing with highly infectious RNA viruses, where demand surges and raw materials are in short supply.
A novel cap analog compound is provided that improves the in vitro transcription efficiency and protein expression efficiency of 5′ capped mRNA by simplifying the synthesis steps and reducing the number of purification steps. The compound of chemical formula 1 is used as the cap analog to reduce the synthesis steps and optimize the purification process.
It improves the efficiency of mRNA synthesis and protein expression, reduces production costs, and is suitable for the rapid and economical production of cap analogs, applicable for the treatment or prevention of diseases in mammals, including humans.
Smart Images

Figure CN118974071A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to a cap analog and a protein expression method using the same, and more specifically, to an mRNA cap analog, a 5′-end capped mRNA comprising the same, a method for preparing the same, a pharmaceutical composition for expressing a target peptide or protein comprising the 5′-end capped mRNA, and a method for producing a target peptide or protein using the 5′-end capped mRNA. Background Art
[0002] RNA therapeutics have recently been proposed as a new paradigm for treating infectious diseases and cancer. In particular, the development of mRNA vaccines by using in vitro transcription has been highlighted as the most promising approach to address RNA viral infectious diseases, capable of overcoming the limitations of conventional vaccines such as attenuated, inactivated, and synthetic antigen vaccines. Since RNA viral infectious diseases are relatively highly contagious and RNA viruses mutate rapidly due to their unstable structures, rapid development of highly safe vaccines is required. mRNA vaccines may shorten the pace of vaccine development because mRNA vaccine candidates can be produced for these infectious diseases within a month and have great safety advantages without the risk of genetic modification because mRNA introduced into the body is decomposed within 24 hours and, unlike DNA vaccines, is translated into proteins by ribosomes in the cytoplasm without entering the nucleus.
[0003] For in vitro transcription of mRNA molecules, the following components are required: a linearized DNA template, an RNA polymerase (mainly T7 RNA polymerase), four ribonucleoside triphosphates (NTPs) A, G, C and U (or m1Ψ, 1-methyl pseudouridine), and a cap analog. If necessary, poly (A) polymerase can be used to perform polyadenylation of 200 to 250 adenosines at the 3' end, and a capping enzyme can be used instead of a cap analog to synthesize a 5' capping structure at the 5' end. Compared with other relatively optimized components, the 5' cap structure, which has a complex structure and plays an important role in the protein translation of mRNA molecules, occupies the highest cost, and extensive research has been conducted to achieve its efficient synthesis.
[0004] After transcription, mRNA undergoes a maturation process to efficiently translate the encoded protein. In this process, 7-methylguanosine (7m The process of connecting the 5′ end of the mRNA molecule to the 5′ end is called the 5′ capping process, and the connected structure is called the 5′ cap structure ( 7m GpppN). The 5' cap structure can protect the 5' end of mRNA from biodegradation by 5' exonucleases and affect the migration of mRNA from the nucleus to the cytoplasm. In particular, the 5' cap structure is recognized by eukaryotic translation initiation factor 4E (eIF4E) to form a translation initiation complex, which plays an important role in protein expression.
[0005] In order for this capped mRNA to be clinically applicable, it must have a structure (Cap1mRNA) in which the 2'hydroxyl group of the first nucleotide connected to the 7-methylguanine nucleoside through a 5'-triphosphate chain is methylated. When the unmethylated Cap0 structure is applied, MDA5 (an intracellular sensor protein) that recognizes the Cap0 structure recognizes the 2'hydroxyl group and induces an immune inflammatory response when the exogenous mRNA with the Cap0 structure is introduced into the body, which impairs the binding of mRNA to elF4E, thereby inhibiting protein expression. In contrast, since the exogenous Cap1mRNA with methylated 2'OH is not recognized by MDA5 even if introduced into the body, it does not induce an immune response and can induce relatively high protein expression, so Cap1mRNA is suitable for clinical trials.
[0006] Examples of commercialized mRNA vaccines based on the above-mentioned Cap1mRNA structure include Moderna's mRNA-1273 and Pfizer's BNT162b2. Both mRNA vaccines were developed to respond to infectious diseases caused by the RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused a global pandemic. In the case of the BNT162b2mRNA vaccine, a co-transcriptional capping method was used, which is an mRNA synthesis method (Co-transcriptional capping method) that simultaneously introduces chemically synthesized cap analogs during in vitro mRNA transcription to make the cap analogs constitute the 5′ end, rather than the conventional capping method (conventional capping method) using a capping enzyme to reduce manufacturing costs.
[0007] The cap analog used in BNT162b2 is AG (3′OMe), as a third generation cap analog, was developed by TriLink (U.S. Patent No. 10,913,768). 7m G (3′OMe) pppA (2′OMe)A trinucleotide cap analog of a pG structure can be introduced during mRNA synthesis to synthesize a Cap1 mRNA structure without the use of an enzyme. Since the trinucleotide cap analog contains at least one more base than GTP, the trinucleotide cap analog has a stronger base pairing hydrogen bond force than GTP in base pairing with the DNA template chain for transcription initiation. Therefore, unlike the previous second-generation cap analog (U.S. Patent No. 7,074,596), which is a dinucleotide cap analog that competes with guanosine triphosphate (GTP) for base pairing with the DNA template, the trinucleotide cap analog can base pair with the DNA template in preference to GTP, thereby reducing the amount of cap analog added during in vitro mRNA transcription, thereby reducing mRNA impurities with a pppG 5′ end.
[0008] Due to the surge in demand for BNT162b2 containing trinucleotide cap analogs in response to the global Covid-19 pandemic, there was a shortage of raw materials. In addition, cap analogs still account for the highest cost in the large-scale production of mRNA vaccines. In order to manufacture mRNA vaccines to appropriately respond to infectious diseases caused by highly contagious RNA viruses, cap analogs need to be produced and supplied quickly and economically.
[0009] The current commercial production process of trinucleotide cap analogs is briefly divided into the following six steps (US Pat. No. 10,913,768).
[0010] [Reaction formula 1]
[0011] G (3′OMe) →pG (3′OMe) →Im-pG (3′OMe) →ppG (3′OMe) →pp 7m G (3′OMe) →Im-pp 7m G (3′OMe) +pN( 2′OMe )pN→ 7m G (3′OMe) pppN (2′OMe )pN
[0012] In reaction formula 1, G is guanosine, 7m G is 7-methylguanosine, N is one of adenosine, cytidine, guanosine and uridine, p is -P(=O)O2-, Me is a methyl group, and Im is an imidazole group. In addition, specifically, if the synthesis of pN (2′OMe) In order to prepare pN (which is a reactant used in the final manufacturing step), a long process of at least 10 steps is required.
[0013] In particular, the main factor that increases the production cost and synthesis cycle in the entire manufacturing process of TriLink's cap analogs for large-scale production is the purification step using ion exchange chromatography (mainly DEAE resin) performed between the steps of the manufacturing process. After purifying the intermediates of each process, a large amount of buffer solution (mainly TEAB, triethylammonium bicarbonate buffer) used for column purification needs to be distilled to carry out the next step in an organic solvent. Since pG is produced in the entire manufacturing process, the production cost is relatively high. (3′OMe) ,ppG (3′OMe) ,pp 7m G (3′ome) , pN (2′OMe) pN and 7m G (3′OMe) pppN (2′OMe) Each step of pN requires purification, so a total of 5 ion exchange column purifications are required. This long process, column purification, and distillation of buffer solutions increase the time and cost of manufacturing cap analogs, thereby reducing economic feasibility. Summary of the invention
[0014] Technical issues
[0015] Provided is a cap analog that can improve the in vitro synthesis efficiency of 5' capped mRNA molecules, improve the protein expression efficiency of the capped mRNA, and be economically produced by reducing the number of steps in the synthesis of the cap analog and the number of purification processes.
[0016] An mRNA 5'-capped with the cap analog is provided.
[0017] A method for preparing mRNA using the cap analog is provided.
[0018] Provided is a composition or kit for preparing 5'-capped mRNA, comprising the cap analog.
[0019] Provided is a pharmaceutical composition for expressing a target peptide or protein, comprising the cap analog.
[0020] A cell comprising mRNA 5'-capped with the cap analog is provided.
[0021] A cell comprising a protein or peptide translated from an mRNA 5' capped with the cap analog is provided.
[0022] Technical Solutions
[0023] According to one aspect of the present disclosure, there is provided a compound of the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
[0024] [Chemical formula 1]
[0025]
[0026] in
[0027] n = 0, 1 or 2;
[0028] Y1, Y2 and Y3 are each independently O or S;
[0029] R1 is C 1-6 Alkyl or CH2Ph;
[0030] R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl, 2,2,2-trichloroethanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, 4-nitrobenzenesulfonyl and 5-dimethylaminonaphthalene-1-sulfonyl;
[0031] R4 and R5 are each independently OH or methoxy;
[0032] R6 is OH or a mononucleotide or oligonucleotide having 1 to 7 bases; and
[0033] Z and Z' are each independently a natural, modified or unnatural nucleobase.
[0034] Another aspect provides a cap analog, which is a compound of Chemical Formula 1.
[0035] Another aspect provides an mRNA that is 5'-capped with the cap analog.
[0036] Another aspect provides a method for preparing 5'-capped mRNA, comprising adding the cap analog during mRNA synthesis.
[0037] Another aspect provides a composition or kit for preparing 5'-capped mRNA, comprising the cap analog.
[0038] Another aspect provides a pharmaceutical composition for expressing a target peptide or protein, comprising mRNA 5'-capped with the cap analog and a pharmaceutically acceptable carrier.
[0039] Another aspect provides a cell comprising mRNA 5'-capped with the cap analog.
[0040] Another aspect provides a cell comprising a protein or peptide translated from an mRNA 5'-capped with the cap analog.
[0041] Beneficial Effects
[0042] According to one aspect, the cap analog, such as the trinucleotide cap analog of TriLink, can be used for the synthesis of mRNA to increase the in vitro transcription efficiency of 5'-capped mRNA molecules and increase the expression efficiency of peptides or proteins by capped mRNA. In particular, since the initial protein expression (initial translation) after transfection may be further increased in a cap-dependent translation manner, the cap analog may be particularly suitable for gene expression (e.g., expression of nsp1 in self-amplified RNA) that is important for initial protein expression. In addition, since the cap analog can be synthesized economically in terms of time and cost by reducing the number of synthesis steps and purification times, the cap analog may help to synthesize 5'-capped mRNA with high economic feasibility, while increasing the expression efficiency of peptides or proteins by using capped mRNA.
[0043] Therefore, this cap analog, similar to currently commercialized trinucleotide cap analogs, has the potential to increase the in vitro transcription efficiency of 5′-capped mRNA molecules and significantly increase the expression efficiency of peptides or proteins by capping mRNA, compared to conventional trinucleotide cap analogs, and can be produced economically.
[0044] Therefore, since the cap analog has excellent advantages in terms of efficacy and production cost, the mRNA comprising the cap analog according to the present disclosure may be very effectively used to treat or prevent diseases in mammals including humans. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 is a graph showing the relative 7m G (3′OMe) pppA (2′OMe) The relative in vitro transcription (IVT) yield (%) of pG, which is measured according to one embodiment with the compound (8) of Example 8 or 7m G (3′OMe) pppA (2′OMe) pG was obtained after IVT yield of luciferase mRNA capped with a cap analog.
[0046] Figure 2 is a graph showing the results of measuring the reaction of the compound (8) of Example 8 according to one embodiment or 7m G (3′OMe) pppA (2′OMe) The results of transfecting HEK293T cell lines with luciferase mRNA prepared by in vitro transcription using pG as a cap analog, and measuring luciferase activity over time to quantify the expression level of translated luciferase protein. Mean ± standard deviation (n = 3), ***: P < 0.05, NS: no significant difference.
[0047] Figure 3 is a graph showing the results of total luciferase protein expression levels from 1 hour to 48 hours after transfection, which are calculated using the compound (8) of Example 8 according to one embodiment or 7m G (3′OMe) pppA (2′OMe) The AUC (area under the curve) value after transfection of pG-capped luciferase mRNA was obtained. DETAILED DESCRIPTION
[0048] Hereinafter, the present disclosure will be described in detail.
[0049] Unless otherwise defined, all technical terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although preferred methods or samples are described in the specification, those similar or equivalent methods or samples may also be considered to be within the scope of the present disclosure. Throughout the specification, even if not specified, numerical values are also considered to include the meaning of "about". The contents of all publications disclosed herein are incorporated herein by reference in their entirety.
[0050] Definition of terms
[0051] Unless otherwise specified, the terms used herein have the same meanings as defined below.
[0052] In the context of a complex of a cap analog and a DNA template, the terms "complementary" or "complementarity" as used herein refer to the standard Watson / Crick base pairing rules. For example, the sequence "5'-AGTC-3'" is complementary to the sequence "3'-TCAG-5'". Complementarity need not be perfect; the duplex may contain mismatched base pairs, degenerate or unmatched nucleotides. One skilled in the art can experimentally determine the stability of the duplex by considering a number of variables, including, for example, the length of the oligonucleotide, the base composition and sequence of the oligonucleotide, the incidence of mismatched base pairs, the ionic strength, the composition of the hybridization buffer, and the reaction conditions.
[0053] Complementarity can be "complete" or "total," in which all of the nucleotide bases of the two nucleic acid strands are matched according to the generally accepted base pairing rules; can be "partial," in which only a portion of the nucleotide bases of the cap analog and the DNA target are matched according to the generally accepted base pairing rules; or can be "missing," in which no nucleotide bases of the two nucleic acid strands are matched according to the generally accepted base pairing rules.
[0054] The term "nucleoside" as used herein includes all naturally occurring nucleosides. The most common base rings in naturally occurring nucleosides are purine and pyrimidine rings. Naturally occurring purine rings include, for example, adenine, guanine and N6-methyladenine. Naturally occurring pyrimidine rings include, for example, cytosine, thymine, 5-methylcytosine and uracil. Naturally occurring nucleosides include, for example, ribose, 2'-O-methyl or 2'-deoxyribose derivatives of adenosine, guanosine, cytidine, thymidine, uridine, inosine, 7-methylguanosine or uridine, but are not limited thereto.
[0055] The terms "nucleoside analogs", "modified nucleosides" or "nucleoside derivatives" as used herein include synthetic nucleosides described herein. Nucleoside derivatives also include nucleosides with modified bases and / or sugar moieties, with or without protecting groups, for example, 2'-deoxy-2'-fluorouridine, 5-fluorouridine or the like. The compounds and methods provided herein include these base rings and synthetic analogs thereof, as well as non-natural heterocyclic substituted base sugars and acyclic substituted base sugars. Other nucleoside derivatives that can be used in the present disclosure include, for example, LNA nucleosides, halogen-substituted purines (such as 6-fluoropurine), halogen-substituted pyrimidines, N6-ethyladenine, N4-(alkyl)-cytosine, 5-ethylcytosine, etc. (U.S. Pat. No. 6,762,298).
[0056] The term "modified nucleoside base" refers to a "modified nucleoside" base including, for example, halogen-substituted purines (such as 6-fluoropurine), halogen-substituted pyrimidines, N6-ethyladenine, N4-(alkyl)-cytosine and 5-ethylcytosine.
[0057] The term "C 1-n "Alkyl" refers to a linear or branched saturated hydrocarbon chain containing 1 to n carbon atoms. Examples thereof may include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and n-hexyl, but are not limited thereto.
[0058] In the process of synthesizing a substance, "in situ" means that the next step of the reaction is carried out in the original container without additional purification of the obtained product.
[0059] One aspect provides a compound of the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
[0060] [Chemical formula 1]
[0061]
[0062] in
[0063] n = 0, 1 or 2;
[0064] Y1, Y2 and Y3 are each independently O or S;
[0065] R1 is C 1-6 Alkyl or CH2Ph;
[0066] R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, 4-nitrobenzenesulfonyl and 5-dimethylaminonaphthalene-1-sulfonyl;
[0067] R4 and R5 are each independently OH or methoxy;
[0068] R6 is OH or a mononucleotide or oligonucleotide having 1 to 7 bases; and
[0069] Z and Z' are each independently a natural, modified or unnatural nucleobase.
[0070] Pharmaceutically acceptable salts refer to salts commonly used in the pharmaceutical field, specifically base addition salts. The salts may be, for example, monovalent metal salts, divalent metal salts, amine salts or amino acid salts. The monovalent metal salts may be Na, Li or K salts, the divalent metal salts may be Ca, Zn or Mg salts, the amine salts may be trimethylamine, triethylamine, ammonia, pyridine or picolinate salts, and the amino acid salts may be arginine, lysine or histidine salts, but are not limited thereto.
[0071] The pharmaceutically acceptable salt may be a salt that allows the compound of Chemical Formula 1 to form a stable, electrically neutral form in an aqueous liquid.
[0072] The compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof may be a compound of the following Chemical Formula 1a:
[0073] [Chemical formula 1a]
[0074]
[0075] in
[0076] n = 0, 1 or 2;
[0077] X1, X2, X3 and X4 are each independently a deficiency, or a monovalent metal ion, a divalent metal ion or a combination thereof, wherein X1, X2, X3 and X4 are selected to make the compound of Formula 1 electrically neutral;
[0078] Y1, Y2 and Y3 are each independently O or S;
[0079] R1 is C 1-6 Alkyl or CH2Ph;
[0080] R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, 4-nitrobenzenesulfonyl and 5-dimethylaminonaphthalene-1-sulfonyl;
[0081] R4 and R5 are each independently OH or methoxy;
[0082] R6 is OH or a mononucleotide or oligonucleotide having 1 to 7 bases;
[0083] Z and Z' are each independently a natural, modified or unnatural nucleobase.
[0084] In one embodiment, the monovalent metal ion is selected from Na + , Li + and K + The divalent metal ion is selected from the group consisting of Mg 2+ 、Zn 2+ and Ca 2+ The group composed of.
[0085] In one embodiment, the sulfonyl-containing group is methylsulfonyl, ethylsulfonyl, or p-toluenesulfonyl.
[0086] In one embodiment, C 1-6 The alkyl group is methyl, ethyl, propyl, isopropyl or tert-butyl.
[0087] In one embodiment, in Chemical Formula 1, Z and Z' are each independently a natural purine or pyrimidine base moiety or a modified form thereof. More specifically, Z and Z' can each be independently selected from the group consisting of guanine, adenine, cytosine, thymine, uracil and a modified form thereof, and in one embodiment, Z and Z' are adenine and guanine, respectively.
[0088] In one embodiment, in Chemical Formula 1, R6 is OH, a mononucleotide, or an oligonucleotide having 2 to 5 bases.
[0089] In one embodiment, the compound having the structure of Chemical Formula 1a is as follows.
[0090] In Chemical Formula 1a,
[0091] n = 0, 1 or 2;
[0092] X1, X2, X3 and X4 are each independently missing or Na;
[0093] Y1, Y2 and Y3 are each independently O or S;
[0094] R1 is C1-6 alkyl;
[0095] R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methylsulfonyl, ethylsulfonyl and p-toluenesulfonyl;
[0096] R4 and R5 are each independently OH or methoxy;
[0097] R6 is OH or a mononucleotide or oligonucleotide having 1 to 3 bases; and
[0098] Z is a natural, modified or unnatural nucleobase.
[0099] In one embodiment, R4 is methoxy and R5 is hydroxy.
[0100] In one embodiment, the compound of Chemical Formula 1 is a compound selected from the group consisting of compounds listed in Table 1 below:
[0101] [Table 1]
[0102]
[0103]
[0104] In the abbreviated compound names, G is guanosine, 7mG is 7-methylguanosine, A is adenosine, p is -P(=O)(OH)O-, Es is ethylsulfonyl, Ms is methylsulfonyl, Ts is p-toluenesulfonyl, and Me is methyl.
[0105] The compound of Chemical Formula 1 can be prepared according to the method shown in the Examples. Those skilled in the art can prepare the compound of Chemical Formula 1 by appropriately modifying the method shown in the following Examples, for example, by modifying the reaction conditions, sequence and compounds.
[0106] According to one embodiment, the compound of Chemical Formula 1 can be prepared by the method shown in the following Reaction Formula 2a.
[0107] [Reaction formula 2a]
[0108]
[0109] The details of the preparation method shown in the above reaction scheme are described in the following examples.
[0110] Reaction formula 2a can be briefly represented by the following abbreviations.
[0111] [Reaction formula 2a]
[0112] G (2′TBS) →G (2′TBS,3′OMs,5′OMs) →pp7m G (3′OMs) →Im-pp 7m G (3′OMs) +PA (2′OMe) pG→ 7m G (3′OMs) pppA (2′OMe) pG
[0113] Here, G is guanosine, 7mG is 7-methylguanosine, A is adenosine, p is -P(=O)(OH)O-, TBS is tert-butyldimethylsilyl, Me is methyl, Im is imidazolyl, and Ms is methylsulfonyl.
[0114] According to this preparation method, the compound of Chemical Formula 1 can be prepared through four steps. Therefore, compared with the conventional method of preparing a cap analog, the compound of Chemical Formula 1 can be prepared more economically by reducing the number of steps.
[0115] According to one embodiment, the compound of Chemical Formula 1 can be used as a cap analog. Therefore, a 5'-capped mRNA can be prepared using a cap analog as the compound of Chemical Formula 1.
[0116] Thus, one particular aspect provides a cap analogue that is a compound of Formula 1.
[0117] In addition, a specific aspect provides a method for preparing a 5'-capped mRNA, the method comprising introducing a cap analog as a compound of Chemical Formula 1 during mRNA synthesis.
[0118] In addition, a specific aspect provides a composition or kit for preparing 5′-capped mRNA, which includes a cap analog as the compound of Chemical Formula 1.
[0119] Furthermore, a specific aspect provides use of a cap analogue of the compound of Chemical Formula 1 for mRNA synthesis.
[0120] In addition, a specific aspect provides an mRNA capped 5' with a cap analogue that is a compound of Chemical Formula 1.
[0121] The method for preparing 5' capped mRNA using a cap analog as a compound of Chemical Formula 1 can be performed according to any method known in the art. In one embodiment, the 5' capped mRNA can be prepared by a co-transcriptional capping method, which is an mRNA synthesis method in which a chemically synthesized cap analog is simultaneously introduced during in vitro mRNA synthesis, and the cap analog constitutes the 5' end. Specifically, the method may include: a step of introducing a cap analog as a compound of Chemical Formula 1 into a mixture containing RNA polymerase under conditions in which RNA polymerase transcribes a polynucleotide template; and incubating the mixture for a sufficient period of time to allow transcription of the template. According to one aspect, the cap analog including the compound of Chemical Formula 1 can increase the efficiency of in vitro mRNA transcription, compared to the efficiency of initiation using standard GTP, ATP, CTP or UTP, and subsequently increase the protein expression efficiency of the transcribed capped mRNA during translation. Due to the increased transcription efficiency, the synthesis of mRNA may be increased, for example, by about 10%, about 20%, about 40%, about 60%, about 80%, about 90%, about 100%, about 150%, about 200%, or about 500% compared to synthesizing mRNA using typical methods.
[0122] The cap analog according to one aspect, namely the compound of Chemical Formula 1, can significantly increase the protein expression level of 5′ capped mRNA molecules, compared with the traditional trinucleotide cap analog of TriLink (7mG (3′OMe) pppA (2′OMe) More specifically, mRNA molecules capped with a monosulfonylated cap analog 5′ at a 3′-OH residue of the compound of Chemical Formula 1 can significantly increase initial protein expression after transfection, compared to the conventional trinucleotide 3′-methoxy cap analog (7mG (3′OMe) pppA (2′OMe) pG), thereby significantly increasing the overall protein expression level (see Experimental Example 2).
[0123] The cap analog according to one aspect, ie, the compound of Chemical Formula 1, has the advantage of economical synthesis in terms of time and cost, by reducing the number of synthesis steps and column purification, compared to the trinucleotide cap analog of TriLink.
[0124] In more detail, by selecting optimized starting materials (e.g., G (2′TBS) ) In the preparation of the compound of Chemical Formula 1, the conventional two-step process of converting guanosine into guanosine monophosphate and then into diphosphate can be simplified to a one-step process of directly converting guanosine into diphosphate, and the subsequent guanosine 7-methylation process can be performed in situ to shorten the crystallization / purification process. More specifically, by(2′TBS) ) is mesylated at the 3′ and 5′ OH of the molecule, and then 7-methylguanosine diphosphate (pp 7m G), synthesize 7-methylguanosine diphosphate (pp 7m G) can be shortened by two steps compared to the conventional method of preparing trinucleotide cap analogs by TriLink (the method of [Reaction Formula 1] below). In addition, as shown in the following reaction formula 1, TriLink prepares trinucleotide cap analogs 7mG (3′OMe) pppN (2′OMe) The pN method requires a total of 5 ion exchange column purifications (to be purified: pG (3′OMe) ,ppG (3′OMe) ,pp 7m G (3′Ome) , pN (2′OMe) pN and 7m G (3′OMe) pppN (2′OMe) pN) (see US 10,913,768), the cap analogue comprising the compound of Chemical Formula 1 can be prepared by ion exchange column purification three times in total, as shown in the following reaction formula 2 (to be purified: pp 7m G (3′OR) , pN (2′OMe) pN and 7m G (3′OR) pppN (2′OMe) pN). Therefore, the cap analog of the compound of Chemical Formula 1 according to one aspect can be prepared by shortening the synthesis process and using a significantly reduced purification process, compared to conventional cap analogs.
[0125] [Reaction formula 1]
[0126] G (3′OMe) →pG (3′OMe) →Im-pG (3′OMe) →ppG (3′OMe) →pp 7m G (3′OMe) →Im-pp 7m G (3′OMe) +pN (2′OMe) pN→ 7m G (3′OMe) pppN (2′OMe) pN
[0127] [Reaction 2]
[0128] G (2′TBS) →G (2′TBS,3′OR,5’OR) →pp 7m G (3’OR) →Im-pp 7m G (3′OR) +pN (2’OMe)pN→ 7m G (3′OR) pppN (2′OMe) pN
[0129] In reaction formulas 1 and 2, G is guanosine, 7m G is 7-methylguanosine, N is one of adenosine, cytidine, guanosine and uridine, p is -P(=O)O2-, TBS is tert-butyldimethylsilyl, Me is methyl, Im is imidazolyl, and R is a substituent selected from the group consisting of p-toluenesulfonyl, p-bromobenzenesulfonyl, p-nitrobenzenesulfonyl, ethanesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, 2,2,2-trifluoroethanesulfonyl and dansyl.
[0130] Therefore, the cap analog of the compound of Chemical Formula 1 according to one aspect has an advantage of further reducing the production time and cost of the cap analog.
[0131] In one embodiment, according to the method for preparing 5' capped mRNA, at least one modified NTP can be further added to the transcription reaction. The modification of at least one modified NTP will not substantially impair RNA polymerase-mediated mRNA synthesis. The modified NTP can include, for example, at least one modified nucleoside base, at least one modified sugar, and at least one modified 5'-triphosphate. Therefore, the modified NTP can be incorporated into the 3' end of the cap analog, which supports additional extension of the primer without blocking transcription. The modified group of the modified NTP can be a detectable label or a detectable marker. Therefore, after transcription, the prepared mRNA containing a detectable label or a marker can be identified by size, quality, color and / or affinity capture. In one embodiment, the detectable label or marker is a fluorescent dye, and the affinity capture label is biotin.
[0132] In one embodiment, one or more components of the transcription reaction (cap analog and / or NTP) can be labeled with a detectable label or marker. Thus, after transcription, the mRNA molecule can be identified, for example, by size, quality, affinity capture and color. For example, the detectable label is a fluorescent dye and the affinity capture label is biotin.
[0133] The kit or composition for preparing 5' capped mRNA can include all common transcription reagents for synthesizing mRNA (e.g., FLuc mRNA). More specifically, the kit can include: a cap analog; a container labeled for transcription; instructions for performing mRNA synthesis; at least one reagent selected from the group consisting of at least one unmodified NTP, at least one modified NTP (e.g., methyl pseudouridine 5'-triphosphate), RNA polymerase, other enzymes, reaction buffer, magnesium, and a DNA template.
[0134] The 5′-capped mRNA prepared using a cap analog according to one embodiment includes the cap analog in its structure, and the 5′-capped mRNA can express a protein in vivo by administering the 5′-capped mRNA to a living organism.
[0135] Thus, another aspect provides a method for expressing a target peptide or protein in vivo, the method comprising administering mRNA comprising a cap analog into a living organism.
[0136] In addition, another aspect provides a pharmaceutical composition for expressing a target peptide or protein, comprising mRNA containing a cap analog and a pharmaceutically acceptable carrier.
[0137] In the present disclosure, "target peptide or protein" refers to any protein to be expressed in vivo. In the present disclosure, mRNA capable of expressing the target peptide or protein is 5'-capped with a cap analog according to one aspect to express the target protein in vivo.
[0138] Depending on the type of target peptide or protein, an in vivo therapeutic or preventive effect on the target disease can be obtained. Therefore, the present disclosure can be used to treat or prevent any disease that can be treated or prevented by expressing the peptide or protein. Diseases that can be treated or prevented by expressing a specific type of peptide or protein are known in the art, and the expression of the peptide or protein can be induced by using the pharmaceutical composition to prevent or treat these diseases.
[0139] In addition, another embodiment provides the medical use of mRNA containing a cap analog for preventing or treating any disease in which in vivo expression of a peptide or protein is effective.
[0140] The pharmaceutical composition and treatment or prevention method can be used for treatment or prevention by using gene replacement therapy, genome editing, cancer immunotherapy or vaccination. In one embodiment, the pharmaceutical composition is an mRNA vaccine.
[0141] The pharmaceutical composition can be formulated to be administered by injection or any appropriate route known to those skilled in the art to treat or prevent a disease. Injectable compositions include, for example, sterile saline solutions as pharmaceutically acceptable carriers. Injectable compositions can be formulated as suspensions in lipids or phospholipids, ribosomal suspensions, or aqueous solutions. Methods for formulating the pharmaceutical composition are well known to those skilled in the art.
[0142] In one embodiment, the pharmaceutical composition may contain the mRNA containing the cap analog as an active ingredient at a concentration of about 0.01% to 1%. The concentration may vary depending on the frequency of administration, dosage, administration method, etc.
[0143] In one embodiment, the pharmaceutical composition can be administered to mammals, particularly humans, and the dosage may vary depending on the individual's health condition, disease severity, body weight, age, race, etc., and experts in the field can determine the appropriate dosage. In one embodiment, the dosage for humans may be in the range of 0.0001 to 100 mg / day, more specifically, in the range of about 0.1 to 50 mg / day.
[0144] According to one embodiment, mRNA containing a cap analog can be introduced into cells in vivo or in vitro to express a protein or peptide.
[0145] Thus, another embodiment provides a cell comprising an mRNA comprising a cap analog according to one aspect.
[0146] Another embodiment provides a cell comprising a protein or peptide translated from an mRNA comprising a cap analog according to one aspect.
[0147] Methods for expressing proteins or peptides in cells in vivo or in vitro using mRNA are known in the art, and proteins or peptides can be appropriately expressed in cells according to conventional methods.
[0148] [Example]
[0149] Hereinafter, the present disclosure will be described in more detail with reference to the following examples. However, the following examples are only used to illustrate the present disclosure, and it is obvious to those skilled in the art that modifications and changes can be made without departing from the scope of the present disclosure and the technical concept defined in the appended claims.
[0150] Abbreviation
[0151] The abbreviations used herein are as follows.
[0152] TBDMS: tert-butyldimethylsilyl
[0153] MsCl: Methanesulfonyl chloride
[0154] TEA.3HF: Triethylamine trihydrofluoride
[0155] THF:Tetrahydrofuran
[0156] ACN: Acetonitrile
[0157] DMS: Dimethyl Sulfate
[0158] PW: Purified Water
[0159] DPS: 2,2′-dipyridyl disulfide
[0160] TEA:Triethylamine
[0161] PPh3:Triphenylphosphine
[0162] DMF: N,N-dimethylformamide
[0163] DMTr:4,4'-dimethoxytrityl
[0164] DTT: dithiothreitol
[0165] IVT: In vitro transcription
[0166] Examples 1 to 3: 7-Methyl, 3′-methanesulfonyloxyguanosine 5′-diphosphoimidazole ester (Im-pp 7m G( 3′OMesyloxy Preparation of ) (3)
[0167]
[0168] Example 1: Preparation of 2′-O-tert-butyldimethylsilyl, 3′-methylsulfonyloxy, 5′-methylsulfonyloxyguanosine (1)
[0169] 2′-O-tert-Butyldimethylsilylguanosine was obtained commercially and used as a starting material without further treatment. 3.97 g (9.99 mmol) of 2′-O-tert-Butyldimethylsilylguanosine was added to 91 ml of anhydrous pyridine, followed by stirring at 0° C. for 10 minutes while slowly adding 2.32 ml (29.97 mmol) of methanesulfonyl chloride. Subsequently, the reaction solution was stirred at 10 to 20° C. for 3 hours. 270 ml of distilled water was slowly added at 0° C., followed by stirring at 5 to 10° C. for 1 hour. The resulting crystals were filtered, washed with distilled water, and then vacuum dried to obtain 4.36 g (yield: 80%) of the target compound (1).
[0170] 1 H NMR (400MHz, DMSO-d6, 25℃): d=10.72(s,0.84H),7.96(s,1H),6.56(1.65H),5.80(d,1H),5.15(d,1H),4.96(m ,1H),4.56~4.62(m,3H,overlapped),3.32(m,3H),3.25(m,3H),0.699(m,9H),-0.014(m,3H),-0.231(m,3H).
[0171] Example 2: Preparation of 7-methyl-3′-methanesulfonyloxyguanosine 5′-triethylamine diphosphate (2)
[0172] 4.2 g (7.59 mmol) of 2′-O-tert-butyldimethylsilyl, 3′ methanesulfonyloxy, 5′ methanesulfonyloxyguanosine (1) was dissolved in 33.6 mL of anhydrous acetonitrile, and 17.81 g (19.73 mmol) of tri(tetrabutylammonium) hydrogen pyrophosphate was added, followed by stirring at room temperature for 48 hours. Then, the reaction solution was stirred at room temperature for 1 hour, while 3.71 mL (22.77 mmol) of triethylamine trihydrofluoride was slowly added. After washing by adding 42 ml of dichloromethane and 42 ml of purified water to the reaction solution, the water layer was separated. After washing by adding 42 ml of dichloromethane to the separated water layer, the water layer was separated again. The pH of the separated water layer was adjusted to 4.0 using glacial acetic acid. 28.79 mL (303.6 mmol) of dimethylsulfuric acid was slowly added to the reaction solution for 30 minutes, followed by stirring at room temperature for 3 hours. During this process, the pH of the reaction solution was maintained at 4.0 ± 0.5 using 1M sodium hydroxide. The reaction solution was extracted three times with 126 mL of dichloromethane to remove unreacted dimethylsulfuric acid, and then the aqueous layer was separated. The separated aqueous layer was titrated to pH 5.5 using 1M sodium hydroxide, and the target compound was separated using a DEAE Sepharose column (140 x 210 mm), and freeze-dried to obtain 1.68 g (yield 30.0%) of the triethylamine salt of the target compound (2).
[0173] 1 H NMR (400MHz, D2O, 25℃): d=6.11(d,1H),5.44(dd,1H),5.02(m,1H),4.74(m,D2O overlapped,1H),4.23(m,2H),4.1(s,3H),3.32(s,3H),3.19~3.13(m,12H),1.28~1.18(m,18H) 31 P NMR (162MHz, D2O, 25℃): d=-7.13(d,1P),-10.77(d,1P).
[0174] Example 3: Preparation of 7-methyl-3′-methanesulfonyloxyguanosine 5′-diphosphoimidazole ester (3)
[0175] 1.0 g (1.36 mmol) of 7-methyl-3′-methanesulfonyloxyguanosine 5′-triethylamine diphosphate (2) was dissolved in 40 ml of dimethylformamide, and 0.93 g (13.6 mmol) of imidazole and 1.50 g (6.8 mmol) of 2,2′-bipyridine disulfide were added. 0.189 mL (1.36 mmol) of triethylamine and 1.78 g (6.8 mmol) of triphenylphosphine were added to the reaction solution, followed by stirring at room temperature for 2 hours. The reaction solution was added to a solution of 0.333 g (2.72 mmol) of sodium perchlorate dissolved in 320 mL of acetone, cooled to 4° C., and then the resulting crystals were filtered, washed with cold acetone, and vacuum dried to obtain 0.83 g (yield 100.0%) of the sodium salt of the target compound (3).
[0176] 1 H NMR (400MHz, D2O, 25℃): d=7.999(s,1H),7.32(s,1H),7.07(s,1H),6.06(d,1H),5 .29(m,1H),4.90(m,1H),4.67(m,1H),4.21~4.08(m,2H),4.05(s,3H),3.29(s,3H) 31 PNMR (162MHz, D2O, 25℃): d=-11.41(d,1P),-19.61(d,1P).
[0177] Examples 4 to 7: Preparation of pA(2′OMe)pG(7)
[0178]
[0179] Example 4: Preparation of N2-isobutyryl-2′,3′-diacetoxy-guanosine (4)
[0180] 2.4 g (3.66 mmol) of N2-isobutyryl-5′-O-DMT guanosine was dissolved in 12 ml of dichloromethane, 1.47 ml (18.3 mmol) of pyridine and 1.78 ml (18.3 mmol) of acetic anhydride were added, followed by stirring at room temperature for 5 hours. 24 ml of ethyl acetate was added to the reaction solution for extraction, followed by washing with 14.4 ml of saturated sodium bicarbonate aqueous solution, 14.4 ml of 20% citric acid aqueous solution and 14.4 ml of distilled water. The organic layer was dried over sodium sulfate and distilled under reduced pressure, and the residue was dried under nitrogen for one day. 36 ml of 3% trichloroacetic acid aqueous solution was added to the dried product, reacted at room temperature for 3 hours, then 24 ml of methanol was added and further reacted for 2 hours and 30 minutes. After the reaction solution was distilled under reduced pressure, 36 ml of dichloromethane and 18 ml of distilled water were added, and then a saturated sodium bicarbonate aqueous solution was added for neutralization. The organic layer was separated, dried over sodium sulfate, and distilled under reduced pressure. The residue of the reduced pressure distillation was dissolved in 12 ml of ethyl acetate and crystallized by slowly adding the solution to 108 ml of hexane. The resulting crystals were filtered, washed three times with 12 ml of hexane, and dried under vacuum to obtain 1.43 g (yield 89.6%) of the target compound (4). LC-MS (ESI, m / z) = 438.16 [M+H + ]
[0181] Example 5: Preparation of (N2-isobutyryl-2′,3′-diacetoxy-guanosyl)-N6-benzoyl-2′-methoxy-adenosyl cyanoethyl phosphate (5)
[0182] 5'-O-DMT-N6-benzoyl-2'-methoxy-adenosine amide was obtained commercially and used as a starting material without further treatment. 1.43 g (3.28 mmol) of N2-isobutyryl-2',3'-diacetoxy-guanosine (4) and 3.78 g (4.26 mmol) of 5'-O-DMT-N6-benzoyl-2'-methoxy-adenosine amide were dissolved in 28.4 mL (0.45 M acetonitrile solution, 12.79 mmol) of 1H-tetrazole and stirred at room temperature for 1 hour. A solution prepared by dissolving 544 mg (2.15 mmol) of iodine in 56.7 ml of a mixed solution of tetrahydrofuran: distilled water: pyridine (v:v:v, 7:2:1) was added to the reaction solution and stirred for 45 minutes. After adding 7.2 ml of 10% sodium thiosulfate aqueous solution to the reaction solution, 43 ml of dichloromethane and 14.3 ml of distilled water were added, and the organic layer was separated. The separated organic layer was dried over sodium sulfate, distilled under reduced pressure, and dried under nitrogen for one day. 21.5 ml of 3% trichloroacetic acid aqueous solution was added to the dried product, reacted at room temperature for 3 hours, and then 14.3 ml of methanol was added and further reacted for 2 hours and 30 minutes. After the reaction solution was distilled under reduced pressure, 21.5 ml of dichloromethane and 10.7 ml of distilled water were added, and then a saturated sodium bicarbonate aqueous solution was added for neutralization. The organic layer separated therefrom was washed with distilled water, dried over sodium sulfate, and distilled under reduced pressure. The residue of the reduced pressure distillation was dissolved in 28.6 ml of dichloromethane and crystallized by slowly adding 86 ml of methyl tert-butyl ether at room temperature. The resulting crystals were filtered and vacuum dried for one day to obtain 2.7 g (yield 87.8%) of the target compound (5). LC-MS (ESI, m / z) = 938.28 [M+H + ]
[0183] Example 6: p(OCE)2A bz (2′OMe)p(OCE)G ib Preparation of (2′,3′OAc)(6)
[0184] 2 g (2.13 mmol) of (N2-isobutyryl-2′,3′-diacetoxy-guanosyl)-N6-benzoyl-2′-methoxy-adenosyl cyanoethyl phosphate (5) and 1.11 ml (4.26 mmol) of bis(2-cyanoethyl)-N,N-diisopropylphosphoramidate were dissolved in 9.47 ml (0.45 M acetonitrile solution, 4.26 mmol) of 1H-tetrazole and stirred at room temperature for 30 minutes. A solution obtained by dissolving 811 mg (3.2 mmol) of iodine in 30 ml of a mixed solution of tetrahydrofuran: distilled water: pyridine (v:v:v, 7:2:1) was added to the reaction solution and stirred for 30 minutes. After adding 20 ml of a 10% sodium thiosulfate aqueous solution to the reaction solution, 100 ml of dichloromethane and 40 ml of distilled water were added, and then the organic layer was separated. The separated organic layer was dried over sodium sulfate and distilled under reduced pressure. The concentrate obtained by vacuum distillation was dissolved in 27 ml of dichloromethane, and the solution was slowly added to 133 ml of methyl tert-butyl ether at room temperature for crystallization. The resulting crystals were filtered and vacuum dried for one day to obtain 2.2 g (yield 92.2%) of the target compound (6). LC-MS (ESI, m / z) = 1124.30 [M+H + ]
[0185] Example 7: Preparation of pA(2′OMe)pG(7)
[0186] 2 g (1.78 mmol) p(OCE)2A bz (2′OMe)p(OCE)G ib (2',3'OAc) (6) was added to a mixed solution of 44 mL of methanol and 44 mL of concentrated aqueous ammonia, and stirred at 50 to 55°C for 24 hours. After the reaction was completed, the solvent was distilled under reduced pressure, and 20 mL of methanol was added to the concentrate, followed by distillation 3 times. The concentrate was dissolved in distilled water and purified using a DEAE Sepharose column and reverse phase chromatography to obtain 1.13 g (yield 70%) of the triethylamine salt of the target compound (7).
[0187] 1 H NMR (400MHz, D2O, 25℃): d=8.44(s,1H),8.12(s,1H),7.90(s,1H),6.07(m,1H) ,5.80(m,1H),4.46~4.01(m,8H),3.45(m,3H)LC-MS(ESI,m / z)=707.13[M+H+]
[0188] Example 8: 7m G (3′OMs) pppA (2′OMe) Preparation of pG(8)
[0189]
[0190] 0.55 g of magnesium chloride was dissolved in 27.5 mL of dimethylformamide. 0.6 g (0.99 mmol) of Im- pp 7mG(3'OMs)(3) and 0.5g(0.55mmol)pA(2'OMe)pG(7) were stirred at room temperature for 24 hours. After the reaction was completed, 275mL of 25mM ethylenediaminetetraacetic acid aqueous solution was added dropwise to terminate the reaction, and the reaction solution was cooled to room temperature and neutralized with 1M sodium bicarbonate aqueous solution. The reaction solution was purified using a DEAE Sepharose column (140x 210mm), distilled, and vacuum dried. The dried solid was dissolved in 2.5ml of distilled water, and then 299mg (2.44mmol) of sodium perchlorate in 15mL of acetone solution was added, cooled to 4°C, the resulting crystals were filtered, washed with cold acetone, and vacuum dried to obtain 0.43g (yield 60.0%) of the sodium salt of the target compound (8).
[0191] Experimental Example 1: In vitro transcription of luciferase mRNA by co-transcriptional capping
[0192] For the mRNA synthesis reaction using the compound of Example 8 as a cap analog, a mixture containing 100 ng / ml firefly luciferase DNA transcription template (including poly A 101), 5 mM ATP, CTP, GTP and TP (1-N-methyl-pseudouridine 5′-triphosphate), 4 mM of the compound of Example 8, 10 U / ml T7 RNA polymerase (New England Biolabs #dy1670), 1 U / ml RNase inhibitor protein, 0.01 U / ml inorganic pyrophosphatase, 40 mM Tris·HCl (pH 8.0), 20 mM magnesium acetate, 1 mM spermine and 10 mM DTT. As a comparative example, under the same conditions, by adding the trinucleotide cap analog of TriLink m7 G (3′OMe) pppA (2′OMe) pG was substituted for the compound of Example 8 to prepare a transcription mixture. Each prepared transcription mixture was reacted at 37°C for 1 to 4 hours. Then, to terminate the reaction, 10 mM Tris·HCl (pH 7.5), 2.5 mM magnesium chloride, 0.1 mM calcium chloride, and 100 U / mL DNase I (Thermo Fisher model #2270A) were added to the reaction and reacted at 25°C for 1 hour. After the reaction was completed, the reaction mixture was lysed using New England Biolabs according to the manufacturer's instructions. The mRNA was purified using an RNA purification kit or reverse phase HPLC. The concentration of the purified mRNA was measured using a Thermo Fisher's Ultraviolet spectrophotometer, and the total amount of mRNA was calculated by multiplying the concentration by the reaction volume. Then, to derive the mRNA in vitro transcription (IVT) yield, the total amount of mRNA synthesized using each different cap analog was divided by the input L-DNA content to quantify the IVT yield value based on the cap analog. Specifically, an IVT yield value of 100 means that 100 μg of mRNA was synthesized using 1 μg of L-DNA. This can be calculated by the following [Formula 1].
[0193] Subsequently, the trinucleotide cap analog from TriLink was added 7m G (3′OMe) pppA (2′OMe) The IVT yield value of pG [Formula 1] was considered as 100%, and the IVT yield value of the compound of each example [Formula 1] was divided by 7m G (3′OMe) pppA (2′OMe) The yield value of pG [Formula 1] was multiplied by 100 to convert the IVT yield of the compound of Example 8 to 7m G (3′OMe) pppA (2′OMe) The percentage (%) of pG can be calculated by the following [Formula 2].
[0194] [Formula 1]
[0195] IVT yield value = total amount of mRNA synthesized / amount of L-DNA added
[0196] [Formula 2]
[0197] IVT yield (%) = (IVT yield value of the compound of each example [Formula 1] / 7m G (3′OMe) pppA (2′OMe) pG IVT yield value [Formula 1]) x 100
[0198] The compound of Example 8 or 7m G (3′OMe) pppA (2′OMe) The IVT yield values of pG were repeated three times independently and the significance was verified by unpaired t-test. Figure 1 shown.
[0199] Reference Figure 1 , confirming that the IVT yield of the compound of Example 8 is comparable to that of the traditional third-generation cap analog 7m G (3′OMe) pppA (2′OMe)The yield of pG is almost the same. Therefore, it is confirmed that the compound according to one embodiment can be used to synthesize 5' capped mRNA with a yield comparable to that of the conventional third generation cap analog. 7m G (3′OMe) pppA (2′OMe) pG equivalent.
[0200] Experimental Example 2: Translation of capped luciferase mRNA in HEK293T cells
[0201] In Experimental Example 1, the compound of Example 8 or 7m G (3′OMe) pppA (2′OMe) The translation activity of luciferase mRNA prepared by in vitro transcription of pG was evaluated in the human embryonic kidney 293T cell line (HEK293T). HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin at 37°C in a 5% CO2 atmosphere. HEK293T cells were cultured at 1×10 5 Cells were seeded at a density of 1:100 cells / well in a 6-well plate. The next day, each well of cells was transfected with 100 ng of mRNA using a transfection reagent (messengerMAX lipofectamine; Invitrogen catalog number LMRNA003): According to the transfection reagent manufacturer's recommendations, 0.3 μL of the transfection reagent was diluted in 5 μL of complex medium (Opti-MEM; Life Technologies) in tube A and incubated at room temperature for 10 minutes, and 200 ng of the prepared capped luciferase mRNA was diluted in 10 μL of Opti-MEM in tube B. After mixing the solutions in tubes A and B, incubate at room temperature for 5 minutes. A vector control without capped luciferase mRNA was prepared in the same manner. Then, the cells were transfected using the incubated mixed solution. Cells were harvested 1, 4, 6, 12, 24, and 48 hours after transfection and incubated using Dual- Luciferase activity was measured using a luciferase assay kit (Promega catalog number E2910) according to the manufacturer's recommendations: After removing the culture medium from the transfected cells, 75 μL of phosphate-buffered saline (PBS) was added. Subsequently, 75 μL of Dual- Reagents were mixed and incubated for 10 minutes, and then the luminescence of firefly luciferase was measured using a luminometer (Perkin Elmer). Then, 75 μL of Digital- Reagent, incubate for 10 minutes, and then measure the luminescence of Renilla luciferase. Calculate the ratio of the luminescence value of firefly luciferase to the luminescence value of Renilla luciferase as a control, and then standardize the relative light unit (RLU, Relative right unit) of luciferase activity per hour. The results are as follows Figure 2 All luciferase activity tests were repeated three times independently and the significance was verified by one-way ANOVA and Tukey post hoc test. In addition, to infer the total luciferase protein expression level from 1 hour to 48 hours after transfection, AUC (area under the curve) was calculated using GraphPad Prism. To obtain the peak area value, the luciferase value for each hour was plotted on the Y axis and the corresponding time value was plotted on the X axis to generate the following graph: Figure 2 Then, the trapezoidal rule of Prism was used to calculate the mRNA capped by the compound of Example 8 and 7m G (3′OMe) pppA (2′OMe) The total luciferase area value of pG-capped mRNA in the total time is shown in the following figure. Figure 3 The formula for calculating area values in Prism is as follows.
[0202] ΔX*(Y1+Y2) / 2
[0203] The mRNA capped by the compound of Example 8 showed much higher expression than conventional 7m G (3′OMe) pppA (2′OMe) Luciferase activity of pG-capped mRNA (see Figure 2 In addition, due to the increase in protein expression in the early stage of transfection, the mRNA capped by the compound of Example 8 showed a higher expression than 7m G (3′OMe) pppA (2′OMe) pG-capped mRNA has higher total protein expression levels (see Figure 3 ).
[0204] based on Figure 2 and Figure 3 , confirmed that a cap analog according to one aspect, in which a sulfonyl group instead of a methyl group is introduced into the 3′-hydroxyl group of methylguanosine, has an effect on increasing protein expression compared with a conventional commercial cap analog.
Claims
1. A compound as shown in the following chemical formula 1, or a pharmaceutically acceptable salt thereof: [Chemical formula 1] in n = 0, 1 or 2; Y1, Y2 and Y3 are each independently O or S; R1 is C 1-6 Alkyl or CH2Ph; R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, 4-nitrobenzenesulfonyl and 5-dimethylaminonaphthalene-1-sulfonyl; R4 and R5 are each independently OH or methoxy; R6 is OH or a mononucleotide or oligonucleotide having 1 to 7 bases; and Z and Z' are each independently a natural, modified or unnatural nucleobase.
2. The compound according to claim 1, wherein the compound has the structure of the following Chemical Formula 1a: [Chemical formula 1a] in n = 0, 1 or 2; X1, X2, X3 and X4 are each independently a deficiency, or a monovalent metal ion, a divalent metal ion or a combination thereof, wherein X1, X2, X3 and X4 are selected so that the compound of Formula 1 is electrically neutral; Y1, Y2 and Y3 are each independently O or S; R1 is C 1-6 Alkyl or CH2Ph; R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, 4-nitrobenzenesulfonyl and 5-dimethylaminonaphthalene-1-sulfonyl; R4 and R5 are each independently OH or methoxy; R6 is OH or a mononucleotide or oligonucleotide having 1 to 7 bases; and Z and Z' are each independently a natural, modified or unnatural nucleobase.
3. The compound according to claim 2, wherein the monovalent metal ion is selected from Na + , Li + and K + The divalent metal ion is selected from the group consisting of Mg 2+ 、Zn 2+ and Ca 2+ The group composed of.
4. The compound according to claim 2, wherein Z and Z' are each independently selected from the group consisting of guanine, adenine, cytosine, thymine, uracil and modified forms thereof.
5. The compound according to claim 2, wherein n = 0, 1 or 2; X1, X2, X3 and X4 are each independently missing or Na; Y1, Y2 and Y3 are each independently O or S; R1 is C 1-6 alkyl; R2 and R3 are each independently H or a sulfonyl-containing group, wherein at least one of R2 and R3 is a sulfonyl-containing group, and the sulfonyl-containing group is independently selected from the group consisting of methylsulfonyl, ethylsulfonyl and p-toluenesulfonyl; R4 and R5 are each independently OH or methoxy; R6 is OH or a mononucleotide or oligonucleotide having 1 to 3 bases; and Z and Z' are each independently a natural nucleoside base.
6. The compound according to claim 1, wherein the compound comprises one selected from the group consisting of compounds represented by the following chemical formula and pharmaceutically acceptable salts thereof: 7m G (3'OEsyl) pppA (2'OMe) pG 7m G (3'OMesyl) pppA (2'OMe) pG and 7m G (3'OTosyl) pppA (2'OMe) pG 7. A 5'-end capped mRNA, wherein the 5'-end capping is performed using the compound according to any one of claims 1 to 6 as a cap analog.
8. A method for preparing 5'-end capped mRNA, comprising adding a cap analog of the compound of any one of claims 1 to 6 during the synthesis of mRNA.
9. A composition or kit for preparing 5'-end capped mRNA, comprising a cap analog of the compound according to any one of claims 1 to 6.
10. A pharmaceutical composition for expressing a target peptide or protein, comprising: mRNA capped at the 5' end using the compound of any one of claims 1 to 6 as a cap analog; and a pharmaceutically acceptable carrier.
11. A cell comprising the 5'-end capped mRNA of claim 7. 12 . A cell comprising a protein or peptide translated from the 5′-end-capped mRNA of claim 7 .
Citation Information
Patent Citations
5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing RNA, expressing proteins and in therapy
CN112119084A
Capped analog and application thereof
CN113603739A
Terminally modified RNA
US20140147454A1
